Quick Order

CD171 / N-CAML1 / L1CAM Antibody (FITC), Rabbit MAb

  • CD171 / N-CAML1 / L1CAM Antibody (FITC), Rabbit MAb, Flow cytometric
DatasheetReviewsRelated ProductsProtocols
Human CD171/L1CAM Antibody Product Information
Immunogen:Recombinant Human CD171 protein (Catalog#10140-H08H)
Clone ID:014
Ig Type:Rabbit IgG
Concentration:5 μl/Test, 0.1 mg/ml
Formulation:Aqueous solution containing 0.5% BSA and 0.09% sodium azide
Preparation:This antibody was obtained from a rabbit immunized with purified, recombinant Human CD171 / N-CAML1 / L1CAM (rh CD171 / N-CAML1 / L1CAM; Catalog#10140-H08H; NP_000416.1; Met 1-Glu 1120) and conjugated with FITC under optimum conditions, the unreacted FITC was removed.
Human CD171/L1CAM Antibody FC Application Image
CD171 / N-CAML1 / L1CAM Antibody (FITC), Rabbit MAb, Flow cytometric
[Click to enlarge image]
Caption:
Profile of anti-CD171 reactivity on HeLa cells analyzed by flow cytometry.
Other CD171/L1CAM Antibody Products
CD171/L1CAM Background

L1 cell adhesion molecule (L1CAM), also designated as CD171, is a cell adhesion receptor of the immunoglobulin superfamily, known for its roles in nerve cell function. While originally believed to be present only in brain cells, in recent years L1-CAM has been detected in other tissues, and in a variety of cancer cells, including some common types of human cancer. L1CAM interacts with a variety of ligands including axonin-1, CD9, neurocan and intergrins, and it has been revealed that the RGD motif in the sixth Ig domain of L1CAM is a binding site for integrins, thus important for nuclear signaling. Disruption of L1CAM function causes three X-linked neurological syndromes, i.e. hydrocephalus, MASA syndrome (mental retardation, aphasia, shuffling gait and adducted thumbs) and spastic paraplegia syndrome. Overexpression of L1CAM in normal and cancer cells increased motility, enhanced growth rate and promoted cell transformation and tumorigenicity. Recent work has identified L1CAM (CD171) as a novel marker for human carcinoma progression, and a candidate for anti-cancer therapy.

Human CD171/L1CAM References
  • Meier F, et al. (2006) The adhesion molecule L1 (CD171) promotes melanoma progression. Int J Cancer. 119(3): 549-55.
  • Gavert N, et al. (2008) L1-CAM in cancerous tissues. Expert Opin Biol Ther. 8(11): 1749-57.
  • Issa Y, et al. (2009) Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med. 87(1): 99-112.
  • Weidle UH, et al. (2009) L1-CAM as a target for treatment of cancer with monoclonal antibodies. Anticancer Res. 29(12): 4919-31.
  • Raveh S, et al. (2009) L1 cell adhesion molecule (L1CAM) in invasive tumors. Cancer Lett. 282(2): 137-45.
  • Wolterink S, et al. (2010) Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res. 70(6): 2504-15.
  • Product nameProduct name
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"